Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| FOXO4-DRI | Melanotan II | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates dosing remains experimental. Mouse studies used 5 mg/kg IV, three times weekly. | Research indicates 250-500 mcg daily via subcutaneous injection during loading, reducing to 250 mcg 2-3 times weekly for maintenance. |
| Timing | No established timing protocol. | Administer 4-6 hours before UV exposure for optimal tanning synergy. Can be taken at any time of day. |
| Cycle Duration | Mouse studies used intermittent dosing (3x/week for several weeks). Human protocols not established. | Loading phase 1-2 weeks, then maintenance as long as desired. Pigmentation fades gradually upon discontinuation. |
| Evidence Level | animal_plus_anecdotal | moderate_human |
FOXO4-DRI is a D-retro-inverso peptide that selectively targets the FOXO4-p53 protein-protein interaction in senescent cells. In senescence, FOXO4 binds p53's disordered transactivation domain (TAD2) in the nucleus, preventing p53 from translocating to mitochondria where it would trigger apoptosis. FOXO4-DRI competitively disrupts this interaction, causing nuclear exclusion of p53 and its redirection to mitochondria, selectively inducing apoptosis in senescent cells while sparing healthy cells. The D-retro-inverso configuration provides protease resistance.
Research indicates dosing remains experimental. Mouse studies used 5 mg/kg IV, three times weekly.
No established timing protocol.
Mouse studies used intermittent dosing (3x/week for several weeks). Human protocols not established.
Melanotan II is a synthetic cyclic analog of alpha-melanocyte-stimulating hormone (alpha-MSH) that non-selectively agonizes melanocortin receptors MC1, MC3, MC4, and MC5. MC1R activation stimulates eumelanin synthesis through tyrosinase upregulation, producing tanning. MC3R activation in the CNS increases libido and produces erectile responses. MC4R activation suppresses appetite. The cyclic structure provides enhanced in vivo stability (half-life 1-2 hours) and increased blood-brain barrier permeability compared to linear alpha-MSH.
Research indicates 250-500 mcg daily via subcutaneous injection during loading, reducing to 250 mcg 2-3 times weekly for maintenance.
Administer 4-6 hours before UV exposure for optimal tanning synergy. Can be taken at any time of day.
Loading phase 1-2 weeks, then maintenance as long as desired. Pigmentation fades gradually upon discontinuation.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →